BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Martin RM, Turner EL, Young GJ, et al. (2024) Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial. Jama |
Woodcock DJ, Sahli A, Teslo R, et al. (2024) Genomic evolution shapes prostate cancer disease type. Cell Genomics. 100511 |
Donovan JL, Hamdy FC, Lane JA, et al. (2023) Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment. Nejm Evidence. 2: EVIDoa2300018 |
Wang A, Shen J, Rodriguez AA, et al. (2023) Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics |
Darst BF, Shen J, Madduri RK, et al. (2023) Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. American Journal of Human Genetics |
Thorn JC, Turner EL, Walsh EI, et al. (2023) Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). Bmc Health Services Research. 23: 610 |
Darst BF, Shen J, Madduri RK, et al. (2023) Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry. Medrxiv : the Preprint Server For Health Sciences |
Hamdy FC, Donovan JL, Lane JA, et al. (2023) Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. The New England Journal of Medicine |
Keeney E, Sanghera S, Martin RM, et al. (2022) Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial. Pharmacoeconomics |
Buhigas C, Warren AY, Leung WK, et al. (2022) The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Molecular Cancer. 21: 183 |